SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.125    -0.875 (-43.75%)
Bid:
1.00
Ask:
1.25
Spread: 0.25 (25.00%)
Market Cap: £1.88m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

Lab-Grown Leather Ltd Progress

21 May 2025 07:00

RNS Number : 4970J
BSF Enterprise PLC
21 May 2025
 

 

 

London, 21 May 2025

 

BSF Enterprise PLC 

 

Lab-Grown Leather Ltd Progress

 

BSF Enterprise PLC (LSE:BSFA) a leading innovator in tissue-engineered materials is pleased to announce significant progress in its 100% owned subsidiary, Lab-Grown Leather Ltd ("LGL"), a pioneer in the development of sustainable, high-quality, lab-grown leather. LGL is applying its patented advanced tissue engineering platform (ATEP™) to create leather alternatives for high-value markets, including luxury goods, aerospace, and automotive.

Product Development Highlights

LGL is developing three core product lines:

Elemental Leather™: Premium, high-end luxury leather, identical in feel, look, and smell to traditional leather. It is 100% lab-grown, free of scaffolds and additives.

Elemental+™: High-performance, lightweight, and thin new-age leather.

Elemental X™: Novel leather enabled by engineering biology, AI, and a proprietary cell expression system. This includes the groundbreaking T-Rex leather.

Elemental+™: New Ultra-Thin and Strong Leather

LGL has achieved a significant breakthrough with Elemental+™. Traditional animal leather loses integrity and strength when processed below 0.4mm. However, Elemental+™ can be produced at an astonishing thickness of just 0.04mm - a hundred times thinner than the thickest traditional leather-while maintaining comparable strength and durability. This has been achieved using vegetable-derived tanning components, making it more environmentally friendly. This innovation, and associated new patent filing, opens new possibilities for applications in sectors where weight is critical, such as sportswear, electric vehicles, and aerospace.

Dr Che Connon of Lab-Grown Leather Ltd. stated, "Elemental+™ is a testament to the power of our Advanced Tissue Engineering Platform and our commitment to pushing the boundaries of what biofabricated materials can achieve. We've engineered a new form of leather that retains the desirable properties of traditional leather while offering a level of thinness and strength previously unattainable. This opens up entirely new design and functional possibilities for industries where every gram counts."

Elemental X: T-Rex Leather

LGL has also made substantial progress with Elemental X™, including the development of T-Rex leather. This world-first material, to be derived from synthetic T-Rex DNA, has garnered significant media attention. The leather will be grown in LGL's facilities in Newcastle upon Tyne, UK. Unlike other producers, LGL's finished leather contains no synthetic scaffolds or plastics. Elemental X leather can be made from unlimited species types (past or present). In collaboration with The Organoid Company and VML, a subsidiary of WPP plc, we will promote and scale the Lab-Grown T-Rex Leather product. Given its unique nature and limited initial availability, T-Rex leather is expected to be exclusive and priced at a substantial premium.

Media around the announcement has been a global hit covering an audience of over 500M, a 2.5M estimated print circulation, 38 individual articles and over 2.5K likes, comments and shares on social media platforms, with a predicted view of 1.75M

Following this we have had 3 commercial conversations with new leads in fashion and accessories which are ongoing with a view to partnering to produce the world first T-rex leather product.

Traditional Leather Partnerships

LGL in 2025 has established a working partnership with another significant fashion brand and is currently continuing to work with three other major fashion brands. These brands are paying LGL to produce samples for assessment and development. Progress is being made confidently, albeit at a measured pace, with these samples being tested and assessed.

To date eight 10x10cm2 samples have been sent out this year to multiple companies, as part of an iterative process their supportive feedback has resulted in notable improvements to the Elemental LeatherTM product to further improve the look, feel and suitability for down-stream processing.

Continuous improvement

LGL production plans are set for significant growth and 3DBT's City-Mix™ media additive will offer substantial savings. Over next 5 years the purchase and use of City-Mix™ from 3DBT will save Lab-Grown Leather Ltd over £500k in tissue production costs, helping to further bring down the cost of the Elemental Leather™ whilst representing an additional revenue stream for 3DBT.

 

Contact Information For further information, please visit: www.bsfenterprise.com

 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free platform, BSF aims to deliver sustainable alternatives to traditional materials and meet global demand for environmentally responsible innovations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPPUMUAUPAPPU
Date   Source Headline
4th Dec 20247:00 amRNSOversubscribed Fundraising of £500,000
8th Nov 20247:00 amRNSPortfolio Update
26th Sep 20247:00 amRNSPortfolio Update
12th Aug 20247:00 amRNSKerato Ltd Partners with University of Montreal
18th Jun 20247:00 amRNSDirector/PDMR Shareholding
17th Jun 20247:00 amRNSDirector/PDMR Shareholding
14th Jun 202410:47 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSGrant of Options
11th Jun 20247:00 amRNSInterim Results
11th Apr 20247:00 amRNSSuccessful Cultivated Leather PoC Agreements
20th Mar 202412:56 pmRNSResult of Annual General Meeting
20th Mar 202410:19 amRNSUniversity Collaborations
14th Mar 20247:00 amRNSInvestor Evening
7th Mar 20247:00 amRNSBSF Enterprise and Ivy Farm Enter Partnership
29th Feb 20247:00 amRNSMoU with Sustainable Fashion Company
26th Feb 20247:27 amRNSNotice of AGM
22nd Feb 20247:00 amRNSKerato Limited - Update
15th Feb 20247:00 amRNSStrategic Update
31st Jan 20247:00 amRNSFull Year Results
8th Dec 20237:00 amRNSFOODTECH Joint Venture with CellRev
30th Nov 20233:07 pmRNSStandard form for notification of major holdings
24th Nov 20237:00 amRNS3D Bio-Tissues Product Partnership Progress
26th Oct 20237:00 amRNSNew Cornea Company & Investor Update
9th Oct 20239:34 amRNSParticipation in The ThinkEquity Conference
26th Sep 20232:32 pmRNSResults of General Meeting & Allotment of Shares
18th Sep 20237:00 amRNS3D Bio-Tissues receives EUR612,000 grant
11th Sep 20237:00 amRNSStrategic Update
7th Sep 20239:46 amRNSPublication of Prospectus & Notice of GM
17th Jul 20237:00 amRNSCity-Mix Bio-Pharmaceutical Update
3rd Jul 20239:56 amRNSOpens Office in Hong Kong
29th Jun 20237:00 amRNSInterim Results
23rd Jun 202311:30 amRNSCultivated Meat Approved for Consumption in US
8th Jun 20237:00 amRNSUS Investor Roadshow & Appointment of US IR Agency
1st Jun 20237:00 amRNSPublication of New Research
30th May 20237:00 amRNSSuccessful Cultivated Meat Test
25th May 20237:00 amRNSAdmittance to trading on the OTCQB Venture Market
22nd May 20237:00 amRNSCommercial Progress Update
15th May 20237:00 amRNSLab-Grown Leather Update and Innovation Award Win
21st Apr 20237:00 amRNSShowcase Meat Update
14th Apr 20238:00 amRNSAdmission of Placing Shares & Subscription Shares
12th Apr 20233:35 pmRNSUpdate to Oversubscribed £2.9 million fundraise
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 20237:00 amRNSOversubscribed £2.9 million fundraise
15th Mar 202311:59 amRNSResult of Annual General Meeting
15th Mar 20237:00 amRNSAGM Statement
9th Mar 20238:53 amRNSApplication for Trading on US OTCQB Venture Market
6th Mar 20237:00 amRNSCity-Mix Commercial Progress Update
20th Feb 20233:00 pmRNSNotice of AGM
10th Feb 20237:00 amRNSAllotment of shares
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.